Mereo BioPharma Group plc

Mereo BioPharma develops therapeutics for rare diseases: setrusumab (monoclonal antibody) for osteogenesis imperfecta, alvelestat (serine protease inhibitor) for alpha-1 antitrypsin deficiency-associated lung disease, and vantictumab (monoclonal antibody) for autosomal dominant osteopetrosis type 2.